{"analyses":[{"groupDescription":"Two-stage, minimax design was used to test the null hypothesis that the overall response rate was 30% vs. a 50% alternative.","groupIds":["OG003"],"nonInferiorityType":"SUPERIORITY","pValue":">0.10","statisticalComment":"The number of responders required to reject the null hypothesis was 16 or more.","statisticalMethod":"Binomial exact test"},{"groupDescription":"Two-stage, minimax design was used to test the null hypothesis that the overall response rate was 50% vs. 70% alternative.","groupIds":["OG004"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"The follicular subgroup did not reach its accrual goal and was closed."},{"groupDescription":"Two-stage, minimax design was used to test the null hypothesis that the overall response rate was 30% vs. a 50% alternative.","groupIds":["OG005"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.10","statisticalComment":"The number of responders required to reject the null hypothesis was 16 or more.","statisticalMethod":"Binomial exact test."}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"39"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG000","title":"Phase I, All Histologies, Lenalidomide 15 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG001","title":"Phase I, All Histologies, Lenalidomide 20 mg"},{"description":"Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG002","title":"Phase I, All Histologies, Lenalidomide 25 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG003","title":"Phase II, Diffuse Large B-Cell Subtype"},{"description":"Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG004","title":"Phase II, Follicular Subtype"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG005","title":"Phase II, Lymphoma NOS"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only phase II patients were assessed for overall response.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Overall Response Rate (Phase II)","type":"PRIMARY","unitOfMeasure":"Participants"}